Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$163.08 USD

163.08
395,311

+0.82 (0.51%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $162.00 -1.08 (-0.66%) 7:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (51 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Andrew Rocco headshot

The 3 Widest Competitive Moats on Wall Street

Competitive moats symbolize a company's sustainable advantage, protecting it from competitors and external threats. Three standout examples illustrate this principle vividly.

Neogen's (NEOG) Q1 Earnings Miss Estimates, Margins Rise

Neogen's (NEOG) Q1 Animal Safety business experiences continued destocking, with channel inventory levels reaching multi-year lows.

Here's Why You Should Invest in Boston Scientific (BSX) Now

Investors are optimistic about Boston Scientific (BSX) on consistent growth and upbeat guidance.

Alcon (ALC) Expands Optical Care Line With Latest Launch

Alcon's (ALC) new TOTAL30 Multifocal lens outwits digital device dryness by delivering nearly 100% water at the lens's surface via a patented Water Gradient Technology.

Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Masimo's (MASI) LiDCO to Boost Hemodynamic Monitoring Post CE Mark

Masimo's (MASI) LiDCO is likely to offer clinicians a BIC solution designed to provide a more complete picture of oxygen delivery.

3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Thermo Fisher's (TMO) Strong End Markets and New Buyouts Aid

Thermo Fisher (TMO) is registering strong growth in the electron microscopy and chromatography and mass spectrometry businesses in the academic and government end market.

Hyperfine (HYPR) Progresses in MRI Space With Latest FDA Nod

Hyperfine's (HYPR) updated Swoop software is expected to make brain imaging more accessible and clinically relevant.

Are Investors Undervaluing Addus HomeCare (ADUS) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here's Why You Should Retain Charles River (CRL) Stock Now

Investors are optimistic about Charles River (CRL) on robust RMS segment growth and upbeat guidance.

ResMed (RMD) Gains From Strong Device Sales Amid Macro Woes

ResMed's (RMD) respiratory care business continues to drive growth and the adoption of bilevel and other non-invasive ventilator solutions worldwide.

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.

enVVeno (NVNO) Plans to Expedite enVVe Development for CVI

enVVeno (NVNO) notes that its capital position is now strong enough to begin the enVVe pivotal study.

Veradigm (MDRX)-FDB Vela to Enhance Pharmacy Connectivity

Veradigm's (MDRX) latest progress with FDB Vela is likely to offer prescribers and patients greater choice and cost transparency.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

Investors are optimistic about Teleflex (TFX), led by growth in Vascular, Interventional and Surgical businesses.

Three Reasons to Add PacBio (PACB) Stock to Your Portfolio

PacBio's (PACB) product development activities raise optimism about the stock.

OPKO Health (OPK) Gets BARDA Contract to Combat Antibody Threats

OPKO Health's (OPK) latest awarded funding is likely to enable the development of novel multispecific antibodies against viral infectious disease threats.

Quest Diagnostics (DGX) to Boost Lab Services With New Pact

Quest Diagnostics (DGX) latest deal will boost dialysis laboratory testing and reduce the laboratory costs of dialysis programs for ESRD patients.

3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2024.

Here's Why You Should Buy Globus Medical (GMED) Stock Now

Investors are optimistic about Globus Medical (GMED) on growing musculoskeletal devices demand and strong industry prospects.

LabCorp (LH) to Expand Diagnostics Services With New Deal

LabCorp's (LH) recent deal will bring together critical expertise, experience and technology from both organizations to improve the delivery of high-quality patient care.

Veradigm (MDRX) Advances Tie-Up to Enhance Care Delivery

Veradigm's (MDRX) new phase of strategic investment is likely to drive innovation and close the evidence gap in behavioral health.

DVA vs. CHE: Which Stock Is the Better Value Option?

DVA vs. CHE: Which Stock Is the Better Value Option?